Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University of Halle-Wittenberg, Halle/Saale, Germany.
Pharmacopsychiatry. 2011 May;44(3):102-8. doi: 10.1055/s-0031-1271687. Epub 2011 Mar 22.
The prepulse inhibition (PPI) of acoustic startle reflex is impaired in schizophrenic individuals compared to normal controls, and has been suggested to be a biomarker for sensorimotor gating. In fact, some cross-sectional studies suggest a different type of effect on PPI changes depending on the kind of antipsychotic treatment but few prospective studies have been conducted to investigate the short-term course of PPI alterations during the first few weeks of treatment. This study aimed to investigate schizophrenic subjects and controls over 4 weeks to analyze the course of PPI changes between groups at baseline and during follow-up, to determine whether potential PPI alterations are influenced by type of antipsychotic medication and whether these alterations are accompanied by changes in psychopathology.
39 schizophrenic patients and 39 controls were enrolled into this open prospective trial. Acoustic startle response (PPI) measurements and clinical (PANSS) performance were obtained shortly after admission and every 14 days for a 4-week follow-up period (T1 to T3).
Patients were treated with first and/or second generation antipsychotics in an open-label design. At baseline (T1) significant deficits were detected between schizophrenic subjects and controls for several PPI conditions. Neither was a relationship between type of antipsychotic treatment and PPI measures detected at baseline and during follow-up, nor was any association with PANSS psychopathology found.
The results of our study confirm previous research on PPI deficits in schizophrenic subjects. As with previous prospective PPI studies in schizophrenic subjects, initial PPI deficits were not observed during the follow-up period, independent of the kind of antipsychotic treatment and severity of psychopathology. These findings may indicate that PPI serves as a biological marker of schizophrenic psychosis and sensorimotor gating independent of type of antipsychotic administered or severity of psychotic symptoms.
与正常对照相比,精神分裂症个体的听觉惊跳反射的前脉冲抑制(PPI)受损,并且已被认为是感觉门控的生物标志物。事实上,一些横断面研究表明,抗精神病药物治疗的类型对 PPI 变化有不同的影响,但很少有前瞻性研究来调查治疗开始后的最初几周内 PPI 改变的短期过程。本研究旨在对精神分裂症患者和对照组进行 4 周的研究,以分析两组在基线和随访期间 PPI 变化的过程,确定潜在的 PPI 改变是否受抗精神病药物类型的影响,以及这些改变是否伴有精神病理学的改变。
这项开放前瞻性试验共纳入 39 例精神分裂症患者和 39 例对照。在入院后不久以及 4 周的随访期间(T1 至 T3),分别进行了听觉惊跳反应(PPI)测量和临床(PANSS)评估。
患者以开放标签的方式接受第一代和/或第二代抗精神病药物治疗。在基线(T1)时,精神分裂症患者和对照组在几种 PPI 条件下存在明显的缺陷。无论是在基线和随访期间,抗精神病药物类型与 PPI 测量之间,还是与 PANSS 精神病理学之间都没有发现任何关系。
我们的研究结果证实了先前关于精神分裂症患者 PPI 缺陷的研究。与之前在精神分裂症患者中进行的前瞻性 PPI 研究一样,在随访期间,独立于抗精神病药物的类型和精神病理学的严重程度,没有观察到初始 PPI 缺陷。这些发现可能表明 PPI 作为精神分裂症精神病和感觉门控的生物学标志物,独立于给予的抗精神病药物类型或精神病症状的严重程度。